234P Effect of palbociclib (PAL) + endocrine therapy (ET) on time to chemotherapy (TTC) across subgroups of patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): Post hoc analyses from PALOMA-2 (P2) and PALOMA-3 (P3)

Authors :: S.-B. Kim
Reshma Mahtani
Janice M. Walshe
Eustratios Bananis
K. Puyana Theall
Richard S. Finn
Véronique Diéras
HS Rugo
Xin-Yun Huang
Anil A. Joy
Sherene Loi
S-A Im
Bethany G. Sleckman
S. Yaroslav
Source :: Annals of Oncology. 32:S461
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Oncology
medicine.medical_specialty
Chemotherapy
Post hoc
business.industry
medicine.medical_treatment
Advanced breast
Endocrine therapy
Cancer
Hematology
Palbociclib
medicine.disease
Hormone receptor
Internal medicine
medicine
business
Human Epidermal Growth Factor Receptor 2

Full Text Access

Tools